| INTRODUC TI ON
N-acylamides, also known as lipoamines, are a family of diverse naturally occurring lipids derived from the conjugation of saturated, unsaturated, or hydroxylated fatty acids to amines such as dopamine, ethanolamine, or amino acids (or simply to amide, as in linoleamide). Recent lipidomic studies confirm the widespread occurrence of N-acylamides in mammalian tissue, including brain. 1 The family includes the endocannabinoid N-arachidonoyl ethanolamide (AEA, also known as anandamide), and the cannabinoid system is the best understood signalling pathway in the class, with cognate G-proteincoupled receptors (GPCRs) CB 1 and CB 2 and well-elucidated pathways for synthesis and degradation of AEA. 2 Other N-acylamides have demonstrated biological effects, but generally the molecular targets or receptors mediating these effects are not yet clear. Moreover several N-acyl amino acids are biologically active (see Ref. 4 
for review). A human biosynthetic enzyme for N-acylglycines,
GLYATL2 (glycine N-acyltransferase-like 2, Ref. 5 ), and N-acyl amide synthase genes genes in gut bacteria 6, 7 further emphasizes their importance. N-arachidonylglycine (NAGly), the first-discovered N-acyl amino acid, is reported to activate the orphan GPCR, GPR18 [8] [9] [10] and the lysophosphatidic acid receptor LPA 5 . 11 NAGly concentrations detected in brain are remarkably high and may exceed AEA. 12 Literature suggests NAGly may be involved in nociception, inflammation, and regulation of ocular pressure. 4 Physiological processes for NAGly beyond GPCR signalling have also been proposed, including modulation of transporters, ion channels, and enzymes, especially the AEA-degrading enzyme, fatty acid amide hydrolase (FAAH, Ref. 4 ).
Here we show that N-acylglycines activate another orphan family A GPCR, namely GPR132 (originally called G2A). The most potent N-acylglycine activators of GPR132 are N-palmitoylglcine (NPGly) and N-linoleoylglcine (NLGly) which have mono-unsaturated or saturated acyl side-chains. NAGly has weak agonist activity on GPR132
and is unlikely to be a physiologically relevant ligand. NPGly and NLGly bear structural similarity to the oxidized fatty acid, 9-HODE, the candidate endogenous GPR132 ligand. [13] [14] [15] Administered orally, NLGly reduces leukocyte migration in a mouse peritonitis model. 16 In vivo and in vitro, NLGly can stimulate production of prostaglandin 15-deoxy-Δ 12,14 -PGJ 2 , an inflammation-resolving eicosanoid, from macrophages and macrophage-like mouse RAW cells, respectively. 16 Biological activity of N-acylglycines and oxidized fatty-acids coincides with GPR132 location, in lymphocytes, 17, 18 monocyte-lineage cells including macrophages 19 and keratinocytes. 20 GPR132 is implicated in diverse functions including nociception, 21, 22 positioning of macrophages at sites of inflamation, 19 haematopoiesis, 23 sensing oxidative stress, 20 regulating macrophage responses in a tumor microenvironment, 24 and microglial colonization from periphery into developing brain (in zebrafish 25 ). However, understanding of GPR132 function has been hampered because multiple other ligands have been published to activate GPR132, and selective pharmacological tools for functional studies have not been available. 
| ME THODS

| Chemicals
N-acyl amino acids and linoleamide were obtained from Cayman Chemical (Ann Arbor, MI, USA). SKF-95667, SB-583355, SB-583831, GSK1820795A, and telmisartan were prepared synthetically.
| Mammalian cell culture
Cell lines were maintained at 37°C in 5% CO 2 . DiscoverX PathHunter (CHO) cells were maintained using 10% heat-inactivated fetal bovine serum (HI-FBS) in Dulbecco's minimal essential media (DMEM):Ham's F-12 (1:1) with 2 mmol/L L-glutamine. Selection was maintained using G418 (800 μg/mL) and hydromycin-B (300 μg/mL).
Rat basophilic leukemia (RBL) cells were maintained in DMEM F12
supplemented with 10% HI-FBS at 37°C and 5% CO 2 . RBL cells stably expressing human GPR132a (RBL-GPR132) were supplemented with G418 (500 µg/mL).
GeneBLAzer™ T-REx™-G2A(GPR132)-NFAT-bla FreeStyle™ 293F cells were maintained according to manufacturer's instructions (ThermoFisher Scientific). For experimentation, cells were perfused with HBS at a rate of ~2 mL/ min (28-30°C) and ratiometric images (350/380 nm) were collected at 5 second intervals using MetaFluor software (Universal Imaging Corporation). Data from multiple individual cells within a field were collated from three independent experiments for analysis.
| Ca
| β-arrestin association assay
hGPR132a and mGPR132 were separately cloned into DiscoverX 
| NFAT reporter gene assay
| Activation of the yeast pheromoneresponse pathway
Modified yeast used to express mammalian GPCRs and measure GPCR activation have been described previously. 26 GPR132 orthologs were cloned into pRS306GPD for chromosomal integration.
Human GPR132a (hGPR132a) was integrated into MMY24 (Gpa1/ G αi3 ) to generate YIG95. GPR132b (hGPR132b) isoform and rat GPR132 (rGPR132) were also integrated into MMY24. Mouse GPR132 (mGPR132) was integrated into MMY23 (Gpa1/G αi1 ). 
| Statistical analysis
Half-maximal activities (pEC 50 and pIC 50 ) were calculated by subjecting technical replicates within an experiment to 4-parameter logistic fitting, using PRISM. Values for pEC 50 and pIC 50 
| RE SULTS
At the outset of this project, we had access to the GPR132 agonist, SKF-95667 ( Figure 1A ). SKF-95667 originates from a collaboration between SmithKline Beecham and CADUS. 28 In this collaboration, synthetic surrogate agonists were identified at orphan GPCRs, by subjecting putative GPCRs to compound screening using the CADUS Half-maximal (pEC 50 ) concentrations and maximal responses relative to a reference agonist (%E max ) for SKF-95667 and other compounds tested in this study are shown in Table 1 .
Obinata et al showed that 10 μmol/L 9-HODE induced Ca 2+ transients in CHO cells overexpressing hGPR132a. 13 Using yeast YIG95, we confirmed 9-HODE as an agonist of hGPR132a, causing a concentration-dependent response (pEC 50 = 5.9 ± 0.14; Figure 2A ).
To further corroborate the ligand pairing, we used two mammalian hosts. Perfusion of rat basophilic leukemia cells expressing hGPR132a (RBL-hGPR132a) with 10 μmol/L 9-HODE induced intracellular Ca 2+ release ( Figure 3A ). No response was detected in parental RBL cells ( Figure 3C ). We also used Chinese hamster ovary cells expressing a C-terminally-tagged version of hGPR132a (CHO-hGPR132a PL ), in the PathHunter assay. 9-HODE induced association between hGPR132a PL and β-arrestin ( Figure 4A ; pEC 50 = 5.4 ± 0.16), similar to results reported by others. 15 Together, these data confirm 9-HODE as an agonist of hGPR132a.
RBL-hGPR132a cells were used to screen 6465 chemically diverse compounds, measuring intracellular Ca 2+ mobilization using the fluorescence imaging plate reader (FLIPR). Among active agonists, SB-583831 was chosen based on its potency and similarity to previously described agonists. 30 (Table 1) , indicating a minimum side-chain length amongst unsaturated N-acylglycines between C 6 and C 16 , for agonist activity.
Linoleic acid had no detectable agonist activity up to 100 µmol/L ( Figure 2D ). We also tested lysophosphatidylcholine (LPC), since this proinflammatory lipid was originally described to activate GPR132.
We could detect no agonist or antagonist activity of LPC in any of the test systems used (Table 1) , consistent with published findings. 13, 15 Lipid order-of-potency (based on yeast pEC 50 values for hGPR132a activation) was NPGly > 9-HODE ≈ NLGly ≈ linoleamide > N-oleoyl-
We tested the effect of replacing glycine with other head groups. N-oleoylserine (NOSer) activated hGPR132a more potently than NOGly ( Figure 2E ; pEC 50 = 5.8 ± 0.07 and 5.1 ± 0.24, respectively). However, NOSer exhibited partial agonism (E max = 21±5%; Figure 2E ) compared with the reference agonist SB-583831, in contrast to N-acylglycine agonists which typically had E max ≥ 80% (Table 1) . N-arachidonyltyrosine (NATyr) was inactive, suggesting a steric limit on the N-acylamide head group for GPR132 binding Note: Number of independent experiment occasions is shown in parentheses (n). Typically four technical replcates were conducted on each experiment occasion. Values based on limited data (n ≤ 2) require further experimentation to confirm. For yeast assays, raw data was normalized to the effect of NPGly (hGPR132a) or 9-HODE (rGPR132a). For β-arrestin assays, raw data was normalized to the effect of SB-583831. NT = Not Tested. For inactive (IA) compounds, top concentration tested is shown (for example, pEC 50 < 4 denotes a compound tested up to 100 µmol/L for which no conentration-response curve could be fitted). For compounds which showed evidence of activity at higher test concentrations, but where no pEC 50 could be fitted, E max (%) is included. Note SKF-95667 behaved as a superagonist (>100% E max ) at both hGPR132a and mGPR132 in β-arrestin assays, and did not activate rGPR132.
( Table 1 ). 2-arachidonylglycerol (2-AG) was inactive on hGPR132a (Table 1) . Several N-acylamides including 9-HODE, NLGly and linoleamide produced bell shaped responses in the hGPR132a yeast assay ( Figure 2 ). In these cases, data at higher concentrations where response was depressed were excluded from curve fitting. The assay is based on yeast growth, and this signal depression was attributed to toxicity because control receptors were also inhibited in the same concentration range ( Figure S1 ). Yeast expressing splice variant hGPR132b 31 were activated by N-acylglycines with similar pharmacology to hGPR132a ( Figure S2 ). . Ligand responses were normalized to the effect of NPGly (for hGPR132a) or 9-HODE (for rGPR132). Data are presented as mean ± SEM (from n = 3 to 7 independent experiments per ligand; four technical replicates were conducted for each condition). N-acylamide ligands caused inhibition of yeast cell growth at concentrations >10 µmol/L or >30 µmol/L, and these were therefore used as the top threshold test concentrations curve-fitting
To examine specificity of N-acylamides for GPR132, we tested three other family-A GPCRs expressed in yeast. GPR68 sequence is related to GPR132, but GPR68 responds to acid pH (protons) and no endogenous lipids are known to activate GPR68. 32 CB 2 binds N-acylamide ligands (AEA and 2-arachidonylglycerol) but has low sequence similarity to GPR132. Adenosine A2a has neither sequence similarity nor comparable ligands to GPR132. 33 In general, the Nacylamides were inactive at GPR68, CB 2 and A2a, indicating they are specific agonists of GPR132 ( Figure S1 ). Unexpectedly, NAGly showed weak partial agonist activity on CB 2 (pEC 50 = 5.6 ± 0.3, E max = 17±2%, n = 3; Figure S1 ). NAGly does not bind CB 2 when tested up to 10 µmol/L, 34 but our data raise the possibility of an interaction between NAGly and CB 2 in higher concentration ranges.
Unexpectedly CP-55,940 also activated hGPR132a ( Figure 2E ; pEC 50 = 5.5 ± 0.13, E max = 102 ± 3%), though more weakly than CB 2 ( Figure S1 ; pEC 50 = 7.6 ± 0.27, E max = 100%). CP-55,940 is a synthetic analogue of the Cannabis sativa constituent, Δ
9
-tetrahydrocannabinol. CP-55 940 also modulates the lysophophaditylinositol receptor, GPR55. 35, 36 GPR132 is the fourth lipid receptor (in addition to CB 1 , CB 2 , and GPR55) modulated by CP-55 940.
To confirm the ligand pairing, we perfused RBL-hGPR132a cells with 10 μmol/L NLGly, which induced intracellular Ca 2+ release comparable to 9-HODE ( Figure 3B&C ). NLGly induced association of hGPR132 with β-arrestin ( Figure 4C ; pEC 50 = 5.5 ± 0.2, E max = 39±4%). NOGly had similar activity to NLGly whereas NPGly and NSGly were less active ( Figure 4C ). N-acylglycines act as less efficacious or less potent agonists to induce hGPR132a association with β-arrestin, compared with 9-HODE, which acts as a full agonist. Family A GPCRs have varying degrees of homology across mammals. Assuming most physiological processes change little through mammalian evolution, specificity for cognate ligands is expected to be conserved even where GPCR sequence conservation is not high, due to selective pressure to retain affinity and activity. hGPR132
This is in contrast to G-protein-mediated signals (in RBL-
and mouse GPR132 (mGPR132) are 68% identical. Thus, GPR132
appears less well-conserved than CB 2 , CB 1 , or GPR68 (respectively 83%, 97%, and 92% identical between human and mouse). No activation of mGPR132 by 9-HODE was originally observed. 14 Those authors concluded GPR132 may have distinct roles in human and rodent, and the late-onset autoimmune syndrome in GPR132-null mice 37 may not be relevant to human. We developed yeast expressing rGPR132. 9-HODE, NPGly, NAGly ( Figure 2F ) and also NLGly and linoleamide ( Figure 2G ) activated rGPR132, with potencies comparable to those observed at hGPR132 (Table 1) . We fused a C-terminal ProLink tag to mGPR132. In HEK293 cells expressing EA-β-arrestin, 9-HODE ( Figure 4D ), SB-583831 ( Figure 4E ), NLGly and NOGly ( Figure 4F ) induced association between mGPR132 PL and β-arrestin.
Ligands inactive at hGPR132 (NHGly, linoleic acid, and LPC) were inactive at mGPR132 and rGPR132 (Table 1 ). In conclusion, the phar- Figure S3B ). GSK1820795A was ≈10-fold more potent than telmisartan as an antagonist of hGPR132 ( Figure S3 ). It was unclear whether GSK1820795A acted as a competitive antagonist of SB-583831, since Hill slope differed from unity (nH = 1.9 for both GSK1820795A and telmisartan; Figure S3B ). Extending antagonist F I G U R E 5 GSK1820795A is a selective antagonist at hGPR132a. Telmisartan analogue GSK1820795A was identified as a GPR132 antagonist through high-throughput screening. Responses of yeast expressing hGPR132a to agonists NPGly (A), NLGly (B), linoleamide (C), and SB-583831 (D) were blocked by GSK1820795A in a concentration-dependent manner. Maximal effects NPGly, NLGly, and linoleamide (A-C) were depressed by GSK1820795A with little effect on EC 50 . In contrast, GSK1820795A caused rightward shifts of concentrationresponse curves to SB-583831 without reducing maximal responses. The effect of telmisartan on hGPR132a and Schild analysis are presented in Figure S3 . Agonist responses of yeast expressing GPR43/FFA3 to propionate were not significantly affected by GSK1820795A (E). Data points show mean ± SD of four technical replicates (non-normalized fluorescent counts) from a representative experiment preincubation time from 5 to 45 minutes had no effect on Hill slope (not shown), suggesting non-unity Hill slopes were not caused by insufficient binding equilibration. We concluded that N-acylglycines and SB-583831 have distinct modes of binding to GPR132.
To probe further the interaction of GPR132 with lipids, we predicted a 3D pose for N-acylglycine and 9-HODE binding, and tested this by mutagenesis. A 3D homology model of hGPR132
from GPCRdb was used. 38 Due to the flexible acyl side-chain of both ligands, we adopted an "anchor and grow" approach (see Figure S6 ). 9-HODE is similar to ligands of FFA 1 . Carboxylate-binding residues in FFA 1 have been established by mutagenesis 39 and crystallization. 40, 41 We hypothesized that lipid heads groups bind GPR132 in an equivalent pocket, so we focused on this region as the initial anchoring site (residues 4.57, 5.39, 5.42, 6.51, and 6.55
by Ballesteros-Weinstein numbering). Meta-analysis of the ternary complex between FFA 1 , fatty-acid mimetic MK-8666 and allosteric ligand AP8 further supported importance of these residues ( Figure   S4 ). "Anchor and grow" docking yielded superimposable and reproducible low-energy-scoring binding poses for 9-HODE and NPGly.
Growth trees with the best grid scores are shown in Figures S6 and S7. The lowest-energy binding poses for 9-HODE and NPGly are highly similar (Figure 6 ). At neutral pH, negatively charged lipid headgroups are predicted to stabilize a charge network involving Y200 (5.39), Y258 (6.51), K265 (6.58), and K183 (ECL2). We noted a potential interaction between R203 (5.42) and the alkyl side chain of both 9-HODE and NPGly. This residue is conserved across GPR132
orthologs. In published GPCR structures, residue 5.42 often lines the "classical" ligand-binding pocket. Residue 5.42 tends to contribute more to agonist than antagonist binding ( Figure S5 ). We mutated R203 (5.42) and adjacent residues Y199 (5.38) and Y200 (5.39) of hGPR132a, and also K183 in ECL2. Agonist potencies for a panel of ligands is shown in Figure 7 and Table S1 . Mutant R203A (5.42) abolished responses to NPGly and NLGly ( Figure 7C and D) . These effects were unlikely to be due to reduced expression of hGPR132a, since R203A responded to CP-55,940 with a potentiated response (wild-type: pEC 50 = 5.64 ± 0.08; R203A: pEC 50 = 7.04 ± 0.06; Figure 7B and Table S1 ). These observations are consistent with We corroborate 9-HODE as a candidate endogenous agonist for hGPR132. 14, 15 Our data are consistent with activation of G αi pathways by GPR132. 13 Chimeric Gpa1-G αi3 supported hGPR132 signalling in yeast, and G αi activation in RBL cells has been shown to trigger Ca 2+ mobilization. 42 We show for the first time that rGPR132
and mGPR132 are also activated by 9-HODE. Broadly, 9-HODE and N-acylglycines have comparable effects on GPR132, which is unsurprising given their similar structures.
N-acylserine (NOSer; Figure 2 ) and N-acylalanine 6 also activate GPR132, though N-acylglycines appeared most efficacious.
Moreover, a specific biosynthetic enzyme for N-acylglycines, GLYATL2, has been characterized suggesting biological relevance.
5
Few N-acyl derivatives of larger amino acids are commercially available. N-arachidonyltyrosine was inactive, but arachidonate is not an optimal side-chain for GPR132 activation. A full understanding of SAR will require a systematic evaluation across N-acyl amino acids with a common, optimal acyl groups for GPR132 activation.
We observed no activation of GPR132 by free linoleic acid up to 100 µmol/L in either yeast or β-arrestin assocation assays, in agreement with, 13 though not. 15 Amidation of linoleic acid to linoleamide confers agonist activity (Figure 2 ). This contrasts with FFA receptors, where fatty acid amidation abolishes agonism. 43 We also disclose SB-583831 and SB-583355 as peptidomimetic GPR132 agonist and antagonist. These are based on amino acid templates (glycine in SB-583831; L-phenylalanine in SB-583355) with structural similarity to previously described agonists. 30 Yeast is suited to GPCR deorphanization because no potentially confounding GPCRs are encoded in the yeast genome (the pheromone receptor, Ste2p, is deleted). Inadvertent upregulation of 50 and three of the four basic amino acids involved in pH-sensing by GPR4, GPR65, and GPR68 are non-basic residues in GPR132. 50 Discovery of 9-HODE allowed direct comparison of the effect of acidic pH to a molecular agonist. 9-HODE was approximately 10-fold more efficacious than acidic pH. 13 Considering these factors, and the challenges in discriminating specific effects of pH on receptors from the effects of pH on host cells, we present here data generated in buffered conditions (constant pH), to show pH-independent agonist effects.
We postulated lipids to enter GPR132 via a crevice between TM4
and TM5 domains and to occupy similar poses. Acyl groups extend through the TM4/TM5 crevice into the lipid bilayer, accommodating larger acyl groups (C 20 in 11-HETE 13 to CB 1 . 54 Together, our data raise the possibility of a comparable pocket on two lipid receptors, CB 1 and hGPR132a, able to accommodate CP-55,940. A limitation of our functional assay data is that it does not distinguish mutational effects on efficacy and affinity.
It will be informative to analyze mutations using probes to directly quantify affinity at GPR132, and reliable antibodies to measure protein expression, when such tools become available. An alternative interpretation is that R203 (5.42) forms a salt-bridge to carboxylate and Y200 (5.39) forms a carboxylate-stabilizing interaction, as observed in the FFA 1 -TAK-875 structure. 41 Confidence in the structure of GPR132 and pose of bound ligands will require crystallography or other biophysical methods.
How does the identification of N-acylglycines as ligands for GPR132 advance understanding of this multi-functional GPCR? In general, N-acylglycines are anti-inflammatory 3, 12 and anti-nociceptive, 12 whilst 9-HODE is proinflammatory 20 and pro-nociceptive. 21 These differences could relate to preferential activation of separate pathways downstream of GPR132. N-acylglycines induced weaker association of ß-arrestin with GPR132 compared to 9-HODE, whereas NPGly activated GPR132-expresssing yeast more strongly than 9-HODE. However, the situation is complicated because 9-HODE also activates PPARγ, a known modifier of macrophage activation. 55, 56 N-acylglycines also are unlikely to be selective for GPR132. 4 Both 9-HODE and N-acylamides (such as AEA) interact with TRPV1. 57 , 58 We have not tested the panel of N-acylglycines at TRPV1, but the GPR132 antagonist SB-583355 is inactive at TRPV1
(tested at a single concentration; 12.5 µmol/L) so might allow confirmation of GPR132-mediated lipid effects in tissue. Structure-activity relationship (SAR) for N-acyl amino acid stimulation of PGJ production by mouse RAW cells 16 resembles, at least in part, order-of-potency at GPR132, with NLGly being more active than NAGly. Thus, RAW cell activation may be mediated by GPR132. However, selective blockade will be required to conclusively attribute GPR132-mediated effects of N-acylglycines and oxidized fatty acids in primary cells, and in vivo. Oxidized fatty acids are produced in skin and other tissues under stress conditions, such as exposure to UV light. Hattori et al found that skin keratinocytes under oxidative stress upregulate GPR132, and 9-HODE treatment causes GPR132-mediated intracellular Ca 2+ release in these cells. 20 The identification of N-acylglycines as GPR132 ligands also points to functions in barrier tissues, since skin fibroblasts express high levels of GLYATL2. 5 N-acylglycines from skin fibroblasts may signal to GPR132 on local keratinocytes, or to infiltrating or tissue-resident macrophages. At sites of zymosan-induced inflammation, GPR132 functions to position infiltrating macrophages into proinflammatory microenvironments, facilitating M1-like differentiation and production of proinflammatory mediators. 19 N-acylglycines signalling to GPR132 in dermis may operate in a similar way.
In conclusion, GPR132 is activated by two lipid classes: oxidized fatty acids exemplified by 9-HODE and 11-HETE, and N-acyl amino acids, exemplified by NPGly and NLGly. Oxidized fatty acids are associated with pathological states such as oxidative stress. N-acylglycines are produced by dedicated biosynthetic pathways under non-pathological conditions. Knowledge of the endogenous ligands of GPR132 will be crucial to fully understand the immunomodulatory roles of this GPCR.
